Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 3/20 | 0.41 |
| ▸ | PLAU | P00749 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TTPA | P49638 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18895847 | 0.89 | PLG (0.37) | PLGPLAUF10KLKB1F2 | |
| SCHEMBL18620596 | 0.85 | PLG (0.41) | PLGPLAUF10KLKB1F2 | |
| SCHEMBL850468 | 0.85 | PLG (0.45) | PLGPLAUF10KLKB1F2 | |
| SCHEMBL8961190 | 0.84 | PLG (0.40) | PLGPLAUF10KLKB1F2 | |
| SCHEMBL4428219 | 0.83 | PLG (0.41) | PLGPLAUF10KLKB1F2 | |
| SCHEMBL4426832 | 0.83 | PLG (0.41) | PLGPLAUF10KLKB1F2 | |
| SCHEMBL4437400 | 0.83 | PLG (0.41) | PLGPLAUF10KLKB1F2 | |
| SCHEMBL4438412 | 0.82 | PLG (0.40) | PLGPLAUF10KLKB1F2 | |
| SCHEMBL4428216 | 0.81 | PLG (0.40) | PLGPLAUF10KLKB1F2 | |
| SCHEMBL16893859 | 0.81 | PLG (0.39) | PLGPLAUF10KLKB1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050988-A1 | DOTAM DERIVATIVES FOR THERAPEUTIC USE | SANOFI (FR) | 2017-02-23 | — | — | US | disclosed |
| US-20170044288-A1 | CARBAMATE, THIOCARBAMATE OR CARBAMIDE COMPRISING A BIOMOLECULAR MOIETY | DSM IP ASSETS BV (NL) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050988-A1 | DOTAM DERIVATIVES FOR THERAPEUTIC USE | SSTR2, SSTR5, SSTR3 | PLG 3494/4885PLAU 1057/4885F10 967/4885 |
| US-20170044288-A1 | CARBAMATE, THIOCARBAMATE OR CARBAMIDE COMPRISING A BIOMOLECULAR MOIETY | CPS1, DDO, GLUL | PLG 495/4885PLAU 2317/4885F10 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.